Treatment of Severe Myoclonic Epilepsy in Infants with Bromide and Its Borderline Variant
Treatment of Severe Myoclonic Epilepsy in Infants with Bromide and Its Borderline Variant
复制标题
用溴化物及其边缘变体治疗婴儿严重肌阵挛性癫痫
DOI：
10.1111/j.1528-1157.1994.tb01780.x
复制
发表时间：
1994
期刊：
影响因子：
5.6
通讯作者：
M. Hara
中科院分区：
文献类型：
--
作者：
H. Oguni;Kitami Hayashi;M. Oguni;Akiko Mukahira;Takashi Uehara;Y. Fukuyama;R. Umezu;T. Izumi;M. Hara
总结：我们研究了溴化物（BR）作为添加治疗在11例婴儿严重肌阵挛性癫痫（SME）和另外11例SME边缘变异（BVSME）患者中的疗效。研究受试者的年龄为8.5-183个月（平均64.4个月）。BR治疗的最长持续时间为37个月（范围4-37个月;平均19.7个月）。22例全身强直阵挛发作（GTCS）患者中，有8例（36%）在引入BR 3个月后效果良好（总发作频率或持续时间减少>75%），9例（41%）有中度效果（减少50-75%）。开始BR治疗12个月后，5例显著改善的患者不再有反应;因此，最终6例效果极佳，2例效果中等。在部分性癫痫发作（n=5）和肌阵挛/失神性癫痫发作（n = 5）患者中，每组仅1例患者在12个月时间点显示中度效应。BR的剂量和血清浓度范围分别为30 - 100 mg/kg（平均58 mg/kg）和64 - 159 mg/dl（平均101 mg/dl）。在12例出现副作用（包括嗜睡、食欲不振和皮疹）的患者中，1例因面部出现广泛痤疮样皮疹而需要减少BR剂量。结果表明，BR治疗对SME和BVSME患者有希望，因此应进一步研究。
Summary: We studied the efficacy of bromides (BR) as add‐on therapy in 11 patients with severe myoclonic epilepsy in infants (SME) and in another 11 with the borderline variant of SME (BVSME). Study subjects were aged 8.5–183 months (mean 64.4 months). Longest duration of BR treatment was 37 months (range 4–37 months; mean 19.7 months). Eight of 22 (36%) of patients with generalized tonic‐clonic seizures (GTCS) had an excellent effect (>75% reduction in total seizure frequency or duration) and 9 (41%) had a moderate effect (50–75% reduction) 3 months after introduction of BR. Twelve months after initiation of BR, 5 of the patients with significant improvement were no longer responsive; ultimately, therefore, 6 had an excellent effect and 2 had a moderate effect. Of those with partial seizures (n=5) and myoclonic/absence seizures (n = 5), only 1 patient in each group showed a moderate effect at the 12‐month time‐point. Dosages and serum concentrations of BR ranged from 30 to 100 mg/kg (mean 58 mg/kg) and from 64 to 159 mg/dl (mean 101 mg/dl), respectively. Of the 12 patients experiencing side effects, including drowsiness, appetite loss, and skin rash, 1 required a reduction in BR dosage because of an extensive acneiform rash on the face. The results show that BR treatment holds promise for patients with SME and BVSME and should therefore be investigated further.